Ancora offers $1.2 billion cash for H.B. Fuller's adhesives unit

H.B. Fuller confirmed receipt of an unsolicited $1.1 billion to $1.2 billion cash proposal from Ancora Holdings for its Building Adhesive Solutions segment, a deal that would fund the adhesives maker's deleveraging.

"We are formally proposing that Ancora acquire the Company's BAS segment for between $1.1 billion and $1.2 billion in cash," Fredrick D. DiSanto, chairman and chief executive officer of Ancora Holdings Group, said in an Aug. 12 letter to H.B. Fuller's board.

The all-cash offer, which Ancora said carries no financing contingency, would hand the St. Paul, Minnesota-based company a substantial source of capital as it integrates its pending acquisition of Advanced Medical Solutions plc. Ancora, which manages $11.7 billion in assets and describes itself as a meaningful H.B. Fuller shareholder, first approached Chief Executive Officer Celeste Mastin and Board Chair Teresa Rasmussen privately on July 7 but said it received no substantive response. The proposal is subject to board and shareholder approvals, regulatory clearance under the Hart-Scott-Rodino Act, confirmatory due diligence and a definitive agreement.

A sale would let H.B. Fuller exit a lower-margin operation competing in a fragmented market while sharpening its portfolio around higher-priority businesses and Project Quantum Leap. The question now is whether the board engages on a transaction that could resolve Ancora's activist campaign rather than trigger a prolonged fight over board seats.

A Deal Built Around Deleveraging

Ancora framed the carve-out as a win-win that would accelerate debt reduction while freeing management to focus on integrating AMS, the medical adhesives maker H.B. Fuller agreed to acquire. The investor said its $1.1 billion to $1.2 billion range is based entirely on publicly available information and that it would raise the price if due diligence uncovers additional value in the segment.

The proposal carries an attractive purchase multiple, Ancora said, and the firm would require only a customary due diligence window given its familiarity with the business. Olshan Frome Wolosky LLP is serving as Ancora's legal advisor, with operating partners participating in evaluating the segment and preparing a transaction.

Ancora said it has the financial wherewithal to complete the acquisition without a financing contingency, backed by $11.7 billion in assets under management and institutional and private client relationships that could supply additional capital if needed. The firm said it is prepared to enter a confidentiality agreement immediately to begin diligence.

The letter, signed by DiSanto and James Chadwick, president of Ancora Alternatives, struck a combative tone, accusing H.B. Fuller leadership of a "preference for entrenchment" and of delivering "ineffective media interviews" that have done nothing to boost the company's value or fix its leverage issue. Ancora said it had hoped to avoid making the proposal public but felt compelled to inform fellow investors after a month without a substantive response.

Activist Pressure Mounts

The offer marks the latest step in Ancora's campaign at H.B. Fuller, which the investor has criticized over capital allocation, leverage and the AMS deal. Ancora recently entered a cooperation agreement with Ashland Inc., another specialty chemicals company, and has signaled willingness to pursue governance changes across its portfolio.

At H.B. Fuller, however, Ancora is presenting an asset sale as an alternative to a prolonged effort to replace board members. The firm said it would rather begin working together on a transaction than run a multi-year campaign to remove and replace directors due to what it called chronic underperformance.

The immediate question is whether H.B. Fuller's independent directors will engage. Ancora has asked them to determine whether the company is willing to explore a transaction and, if so, to begin confidentiality and diligence discussions. At as much as $1.2 billion in cash, the proposal gives H.B. Fuller a concrete option for monetizing Building Adhesive Solutions while reducing leverage and sharpening its portfolio around other strategic priorities.

If the board declines to engage, Ancora has signaled it could escalate its campaign, having already threatened a multi-year effort to replace directors. If it engages, a carve-out could close within months, subject to regulatory review and a definitive agreement. Either path leaves H.B. Fuller, the world's largest pureplay adhesives company, at a strategic crossroads as it weighs portfolio simplification against the demands of an activist shareholder.

This article is for informational purposes only and does not constitute investment advice.